Encephalopathy autoimmune evaluation, spinal fluid

Alphabetical Test listing

Encephalopathy autoimmune evaluation, spinal fluid-12689

Encephalopathy autoimmune evaluation, spinal fluid
  • Evaluating new onset encephalopathy (noninfectious or metabolic) comprising confusional states, psychosis, delirium, memory loss, hallucinations, movement disorders, sensory or motor complaints, seizures, dyssomnias, ataxias, nausea, vomiting, inappropriate antidiuresis, coma, dysautonomias, or hypoventilation in spinal fluid specimens

    The following accompaniments should increase of suspicion for autoimmune encephalopathy:
    • Headache
    • Autoimmune stigmata (personal or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)
    • History of cancer
    • Smoking history (20+ pack years) or other cancer risk factors
    • Inflammatory cerebral spinal fluid (or isolated protein elevation)
    • Neuroimaging signs suggesting inflammation
  • Evaluating limbic encephalitis (noninfectious)
  • Directing a focused search for cancer
  • Investigating encephalopathy appearing in the course or wake of cancer therapy and not explainable by metastasis or drug effect
Cerebrospinal fluid (CSF)

Sterile vial/container

4.0 mL
2.0 mL

Sterile vial/container


Refrigerated (preferred) - 28 days

Frozen - 28 days

Ambient - 72 hrs

Mayo Clinic Laboratories (ENC2): R-MM
8 - 11 days

Indirect Immunofluorescence Assay (IFA), Cell Binding Assay (CBA), Western Blot (WB) and Immunoprecipitin Assay (IPA)

86255 x19

Additional CPT codes (if appropriate):
84182 x 7
86255 x 7
86256 x 8